Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14-16 weeks: a randomized trial.

Autor: Borgatta L; Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA 021128, USA. lynn.borgatta@bmc.org, Roncari D, Sonalkar S, Mark A, Hou MY, Finneseth M, Vragovic O
Jazyk: angličtina
Zdroj: Contraception [Contraception] 2012 Nov; Vol. 86 (5), pp. 567-71. Date of Electronic Publication: 2012 Jun 06.
DOI: 10.1016/j.contraception.2012.05.002
Abstrakt: Background: Cervical preparation is recommended before second-trimester abortion. We investigated the use of a pharmacologic method of preparation, mifepristone, as compared to osmotic dilators for surgical abortions at 14-16 weeks.
Study Design: This was a randomized, parallel-group study with concealed allocation. Women were allocated to receive osmotic dilators or mifepristone 200 mg orally 24 h prior to abortion. The study population was 50 women seeking surgical abortion at 14-16 menstrual weeks in a hospital-based abortion service. The primary outcome was the length of time to perform the procedure; the study had 80% power to detect a difference of more than 3 min in procedure time. Secondary outcomes included cervical dilation, side effects and acceptability.
Results: The mean abortion time for the osmotic dilator group was 8.00 min [95% confidence interval (CI) 6.75-11.47], and that for the mifepristone group was 9.87 min (95% CI 8.93-11.36). Side effects of pain were more common in the osmotic dilator group.
Conclusion: Mifepristone did not increase the time for abortion by more than the prespecified margin (3 min). Women preferred mifepristone to osmotic dilators.
(Copyright © 2012 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: